司美格鲁肽是全髋关节置换术患者比减重手术更安全的体重管理选择吗
该单中心回顾性研究比较了有减重手术史(224例)、围手术期使用司美格鲁肽(202例)和体重指数>35的对照组(2991例)行初次择期全髋关节置换术的患者,发现司美格鲁肽组与减重手术组在假体生存率和术后并发症率上相似,司美格鲁肽似乎是减重手术的安全替代方案,但需进一步研究。
要点
- 司美格鲁肽组与减重手术组在假体生存率和术后并发症率上相似。
- 减重手术组和司美格鲁肽组术前一年至术后一年体重指数分别降低1.4和0.8,对照组增加0.4。
- 较高的美国麻醉医师协会分级和Charlson合并症指数≥5与并发症增加相关。
核心结论
- 司美格鲁肽似乎是全髋关节置换术前体重管理的一种安全替代减重手术的方案,假体生存率和术后并发症率相似。
- 需要进一步研究以了解使用司美格鲁肽的全髋关节置换术患者的结局。
研究设计与样本
- 单中心、城市、学术中心的回顾性研究,纳入2012年至2024年间进行的初次择期全髋关节置换术患者。
- 研究识别了有减重手术史的患者224例、围手术期使用司美格鲁肽的患者202例,以及体重指数>35的对照组患者2991例。
- 比较了各队列之间的人口学变量和临床结局。
主要发现
- 减重手术组患者较司美格鲁肽组和对照组更年轻(57岁 vs 61岁 vs 61岁,P=0.012),女性比例更高(65.6% vs 57.4% vs 55.4%,P<0.001)。
- 术前糖化血红蛋白在司美格鲁肽组最低(6.2% vs 5.7% vs 5.8%,P<0.001)。
- 全髋关节置换术前一年至术后一年体重指数变化在各组间不同(P<0.001):减重手术组和司美格鲁肽组分别降低1.4和0.8,对照组增加0.4。
- 10年假体生存率为95.5%。
- 未发现任何队列与90天急诊就诊、再入院和全因翻修之间存在相关性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Weight management strategies before total hip arthroplasty (THA) include bariatric surgery and Glucagon-like peptide-1 receptor agonists, including semaglutide. Previous studies have reported higher THA implant failure in patients who had prior bariatric surgery. This study aimed to evaluate semaglutide as a weight management alternative for patients undergoing THA and any effects on perioperative outcomes. METHODS: A retrospective review of primary, elective THAs performed between 2012 and 2024 was conducted at a single, urban, academic center. The study identified 224 patients who had a history of bariatric surgery, 202 patients who had perioperative semaglutide use, and a control group of 2,991 patients who had a body mass index (BMI) > 35. Demographic variables and clinical outcomes were compared between cohorts. RESULTS: The bariatric patients were younger (57 versus 61, P = 0.012) and more often women (65.6 versus 57.4 versus 55.4%, P < 0.001) than semaglutide and control patients. Preoperative hemoglobin A1c was lowest in semaglutide patients (6.2 versus 5.7 versus 5.8%, P < 0.001). The changes in BMI varied across groups one year before and after THA (P < 0.001). The bariatric and semaglutide groups decreased their BMI by 1.4 and 0.8, respectively, and control patients increased by 0.4. Implant survivorship was 95.5% at 10 years. There was no correlation found between any cohort and 90-day emergency department visits, readmissions, and all-time revision. Higher American Society of Anesthesiologists class and Charlson Comorbidity Index ≥ 5 conferred increased complications. CONCLUSIONS: Semaglutide appears to be a safe alternative to bariatric surgery for weight management before THA, with similar implant survival and postoperative complication rates. Further studies are warranted to understand outcomes for THA patients who use semaglutide.
引用
- Alpert Z, Katzman JL, Lajam CM, et al. Is Semaglutide a Safer Weight-Management Option Than Bariatric Surgery for Patients Undergoing Total Hip Arthroplasty (THA)? J Arthroplasty. 2025. PMID: 40907673. doi:10.1016/j.arth.2025.08.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。